{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:38:12Z","timestamp":1790818692685,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2576,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1093\/annonc\/mds107","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T05:30:15Z","timestamp":1339479015000},"page":"2896-2902","source":"Crossref","is-referenced-by-count":45,"title":["A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study"],"prefix":"10.1016","volume":"23","author":[{"given":"A.K.L.","family":"Reyners","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Munck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.L.G.","family":"Erdkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hoekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.I.","family":"Lalisang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.M.","family":"Wymenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Polee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hollema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.T.M.","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schaapveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.H.B.","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds107_bb0010","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/bjc.1998.710","article-title":"Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group","volume":"78","author":"Aabo","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds107_bb0015","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.ejca.2008.06.035","article-title":"Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study","volume":"44","author":"Aravantinos","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds107_bb0020","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds107_bb0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"du Bois","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds107_bb0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/A:1016380917625","article-title":"Aspirin, other NSAIDs, and ovarian cancer risk (United States)","volume":"13","author":"Fairfield","year":"2002","journal-title":"Cancer Causes Control"},{"key":"10.1093\/annonc\/mds107_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejogrb.2009.05.030","article-title":"Cox-2 expression in ovarian malignancies: a review of the clinical aspects","volume":"146","author":"Menczer","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1093\/annonc\/mds107_bb0040","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1525-1438.2006.00855.x","article-title":"The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer","volume":"17","author":"Steffensen","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mds107_bb0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.prp.2007.11.004","article-title":"The prognostic significance of COX-2 and survivin expression in ovarian cancer","volume":"204","author":"Athanassiadou","year":"2008","journal-title":"Pathol Res Pract"},{"key":"10.1093\/annonc\/mds107_bb0050","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/S0753-3322(05)80052-6","article-title":"Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice","volume":"59","author":"Olsen","year":"2005","journal-title":"Biomed Pharmacother"},{"key":"10.1093\/annonc\/mds107_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1093\/annonc\/mds107_bb0060","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1054\/bjoc.2000.1572","article-title":"Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer","volume":"84","author":"Vasey","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds107_bb0065","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds107_bb0070","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds107_bb0075","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: cumulative meta-analysis","volume":"364","author":"Juni","year":"2004","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds107_bb0080","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds107_bb0085","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1200\/JCO.2007.13.8081","article-title":"Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy. Cancer and Leukemia Group B Trial 30203","volume":"26","author":"Edelman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds107_bb0090","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-2407-11-214","article-title":"Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients","volume":"11","author":"Legge","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mds107_bb0095","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2003.07.127","article-title":"Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer","volume":"21","author":"Altorki","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds107_bb0100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/JTO.0b013e31821529a9","article-title":"Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial","volume":"6","author":"Altorki","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mds107_bb0105","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-010-0939-3","article-title":"A multicenter randomized phase II study of sequential epirubicin\/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients","volume":"122","author":"Pierga","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mds107_bb0110","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1200\/JCO.2006.07.4773","article-title":"Randomized phase II trial of docetaxel\/irinotecan with or without celecoxib in de second-line treatment of non-small-cell lung cancer","volume":"24","author":"Lilenbaum","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds107_bb0115","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1200\/JCO.2011.35.5214","article-title":"Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study","volume":"29","author":"Groen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds107_bb0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.lungcan.2004.11.004","article-title":"Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial","volume":"48","author":"Nugent","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mds107_bb0125","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/JTO.0b013e31818de1d2","article-title":"Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy","volume":"3","author":"Schneider","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mds107_bb0130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds107_bb0135","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4 Suppl. 4","key":"10.1093\/annonc\/mds107_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/4.suppl_4.S49","article-title":"Advanced ovarian cancer. Dose intensity","author":"Ozols","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds107_bb0145","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.1996.14.3.800","article-title":"Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer","volume":"14","author":"Lind","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds107_bb0150","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341937509X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341937509X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/11\/2896\/13786220\/mds107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T05:45:46Z","timestamp":1637214346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341937509X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S092375341937509X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds107","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}